German Biotech Company to Market Bromodeoxyuridine Antibody Clone

A German biotechnology company has been awarded the exclusive right to commercialize the most popular bromodeoxyuridine (BrdU) antibody clone for research applications.

Bromodeoxyuridine (BrdU) is a synthetic thymidine analog that can be incorporated into a cell's DNA when the cell is dividing (during the S-phase of the cell cycle). Antibodies against BrdU that are conjugated to fluorescent markers can be used to label these cells, thereby providing visual evidence of cell division.

The most popular BrdU antibody clone, BU1/75 was developed at the Institute of Cancer Research (London, United Kingdom) where it was initially called ICR1. Exclusive worldwide rights to market this antibody have now been awarded to AbD Serotec, the research and diagnostic antibodies unit of MorphoSys AG (Munich, Germany). The agreement will allow development of diagnostic procedures to proceed in a range of formats suitable for various applications such as ELISA, flow cytometry, and immunohistochemistry.

"With this agreement AbD Serotec will become the sole supplier of this important BrdU antibody, a powerful tool to detect cell proliferation and cell kinetics assays," said Dieter Feger, head of AbD Serotec. "This product complements our comprehensive range of high quality cell biology reagents covering key research areas such as apoptosis, cancer, cell signaling, and cell morphology."

Related Links:
Institute of Cancer Research
MorphoSys AG